This evolving evidence base suggests a potential paradigm shift in the management of OSA, where pharmacotherapy could play a central role alongside established device therapies
Chronic pain conditions, including neuropathic pain, fibromyalgia, and certain types of arthritis, have also shown promising responses to Retatrutide treatment
In the meantime, we can use powerful tools to risk-stratify who attains access to these medications, starting with "sicker" patients
Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney
Our doctors review every case to select the optimal dose safely
Retatrutide inherits every structural driver of discontinuation that semaglutide and tirzepatide have, and it adds one of its own: the dose-dependent dysesthesia signal at 9 mg and 12 mg in TRIUMPH-4, reported at roughly 20.9% at the 12 mg dose